Gene · 668
Papers2,198
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,198
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer. | Gastric Cancer | 2025 | 40372586 | PubTator, text mining | PubMed |
Adult Granulosa Cell Tumors of the Ovary With Tubular Differentiation: A Report of 80 Examples of an Underemphasized Feature With Clinicopathologic and Genomic Differences From Other Sex Cord-Stromal Tumors. | Am J Surg Pathol | 2025 | 40326456 | PubTator, text mining | PubMed |
| Functional analysis of a novel FOXL2 mutation in blepharophimosis, ptosis, and epicanthus inversus syndrome type II and elucidation of the genotype-phenotype correlation. | Hum Genomics | 2025 | 40251640 | PubTator, text mining | PubMed |
| Regulation of FOXL2 gene in ovarian granulosa cell tumor by JNK inhibitor. | Sci Rep | 2025 | 40204754 | PubTator, text mining | PubMed |
| Functional analysis of 6 variations in FOXL2. | SAGE Open Med | 2025 | 40166712 | PubTator, text mining | PubMed |
| FOXL2 drives the differentiation of supporting gonadal cells in early ovarian development. | Reprod Biol Endocrinol | 2025 | 40102860 | PubTator, text mining | PubMed |
| Uterine Tumors Resembling Ovarian Sex-Cord Tumors (UTROSCTs): Case Report and Narrative Review of the Literature. | J Clin Med | 2025 | 40094884 | PubTator, text mining | PubMed |
| Epigenetic Perspectives and Their Prognostic Value in Early Recurrence After Hepatocellular Carcinoma Resection. | Cancers (Basel) | 2025 | 40075616 | PubTator, text mining | PubMed |
| Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors. | Int J Gynecol Cancer | 2025 | 39983368 | PubTator, text mining | PubMed |
| Unveiling the role of FOXL2 in female differentiation and disease: a comprehensive review†. | Biol Reprod | 2025 | 39976382 | PubTator, text mining | PubMed |
| Molecular tumor board for gynecologic malignancies: the real-world experience from the Department for Gynecology and Gynecologic Oncology of Kliniken Essen-Mitte. | Int J Gynecol Cancer | 2025 | 39971438 | PubTator, text mining | PubMed |
| Understanding Genetic Regulation of Sex Differentiation in Hermaphroditic Fish. | Animals (Basel) | 2025 | 39858119 | PubTator, text mining | PubMed |
| CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds. | Mol Oncol | 2025 | 39776254 | PubTator, text mining | PubMed |
| FOXL2 Knockdown Inhibits the Progression of Endometriosis. | Am J Reprod Immunol | 2025 | 39776079 | PubTator, text mining | PubMed |
| A novel CUL4B gene variant activating Wnt4/β-catenin signal pathway to karyotype 46, XY female with disorders of sex development. | Biol Res | 2025 | 39773765 | PubTator, text mining | PubMed |
| Complex immunohistochemical and molecular study on 5 cases of ovarian juvenile granulosa cell tumors reveals a consistent alteration in the PI3K/AKT/mTOR signaling pathway. | Diagn Pathol | 2025 | 39773640 | PubTator, text mining | PubMed |
| Ovarian Adult Granulosa Cell Tumors: A Scoping Review of DNA Alterations and Their Known Significance. | Anticancer Res | 2025 | 39740818 | PubTator, text mining | PubMed |
| Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01). | Clin Transl Oncol | 2025 | 39738931 | PubTator, text mining | PubMed |
| Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors. | Cancer Res | 2025 | 39652611 | PubTator, text mining | PubMed |
| The Molecular Landscape of 227 Adult Granulosa Cell Tumors of the Ovary: Insights into the Progression from Primary to Recurrence. | Lab Invest | 2025 | 39615884 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/668/papers?page=5